MYO18A and Alzheimer disease: This in vitro finding positively correlates with the occurrence of in vivo aggregation of TIAF1 in the hippocampi of nondemented, middle-aged humans (age 40–75), and formation of amyloid β, fibrils and plaques in older AD patients (age 70–95) [6].